Grants & Patents
"IGF-I inhibition of doxorubicin activity in breast cancer." American College of Clinical Pharmacy, July 1997 to June 1998. Principal Investigator, 5% effort. Direct Costs: $10,000.
"Inhibition of chemotherapy activity by growth factor upregulation in breast cancer." American Association of Colleges of Pharmacy, December 1997 to November 1998. Principal Investigator, 5% effort. Direct Costs: $12,500.
"Mechanisms of chemoresistance in breast cancer by upregulated growth factor pathways." Susan G. Komen Breast Cancer Foundation, December 1997 to November 1999. Principal Investigator, 25% effort. Direct Costs: $101,343.
"Mechanisms of growth factor attenuation of cell death in chemotherapy treated breast cancer cells." Department of Defense Cancer Research Program, June 1999 to June 2003. Principal Investigator, approximately 56% effort. Direct Costs: $206,340
"IGF-I Survival effects on p-53 induced apoptosis." The Charlotte Geyer Foundation, November 2000 to October 2001. Principal Investigator, 25% effort. Direct Costs: $90,909.
"IGF-I survival effects on p53 induced apoptosis." National Cancer Institute, July 2001 to June 2004. Principal Investigator, 25% effort. Direct Costs: $328,750
"Modulation of Neutrophil Function by cigarette smoke extract." Philip Morris External Research Program, March 2001 to February 2004. Co-Investigator, 5% effort (Principal Investigator: K. Stringer). Total Budget: $513,593
"P53 dependence of IGF-I survival responses through JNK and Akt." Avon Breast cancer Foundation Project Grant, November 2000 to October 2001. Principal Investigator, 5% Effort. Direct Costs: $50,000.
"The relationship between melatonin effects on Tumor Necrosis Factor-alpha in older adults with involuntary weight loss." American Association of Colleges of Pharmacy, December 2000 to November 2001. Co-Investigator, 3% effort (Principal Investigator: R.L. Page). Direct Costs: $10,000.
"The role of JNK in mammary gland development." University of Colorado Cancer Center Seed Grant, funding period February 2004 to January 2005. Principal Investigator, 3% effort. Direct Costs: $20,000
"Characterization of caspase-9 resistance in breast cancer cells." Cancer League of Colorado, funding period July 1, 2004 to June 30, 2004. Principal Investigator, 5% effort. Direct Costs: $30,000
"The role of JNK in mammary gland development and tumorigenesis." National Cancer Institute, December 2004 to November 2009. Principal Investigator, 25% effort. Direct Costs: $1,000,000.
SN 08/376,364, Methods of Human Prostate Cancer Diagnosis, John McGill, Carla Van Den Berg, Jeffrey Trent, Daniel Von Hoff and Paul Meltzer.
More information about Dr. Van Den Berg
> Publications & Abstracts
> Drug Dynamics Institute
> Return to Van Den Berg's Home Page
Pharmacology & Toxicology
College of Pharmacy
The University of Texas
107 W. Dean Keeton
Austin, TX, USA
Email Address: pharmtox
Dr. Som Mukhopad-
hyay led the research team that focused on the gene SLC30A10 and its role as a "door opener" in helping to remove elevated levels of manganese from cells. The study was published in the Oct. 15, 2014 issue of The Journal of Neuroscience.
"Drugs, the Brain and Behavior" is co-authored by Dr. Carlton Erickson, the college's associate dean for research and graduate studies, and Dr. John Brick, executive director of Intoxikon International.
Andrea Gore is named to the SEBM Distinguished Scientist Award.